Tous Actualités
Suivre
Abonner AGENNIX AG

AGENNIX AG

EANS-News: AGENNIX AG
Agennix AG Raises Approximately EUR 76 Million in Net Proceeds in Capital Increase

Heidelberg (euro adhoc) -

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Capital measures
Proceeds expected to enable Company to
obtain topline data in Phase III non-small cell lung cancer trial 
with lead product candidate oral talactoferrin
Planegg/Munich (Germany), October 1, 2010 - Agennix AG (Frankfurt 
Stock Exchange (Prime Standard): AGX/ISIN DE000A1A6XX4) today 
announced that the Company has raised approximately EUR 76 million in
net proceeds in its capital increase via participation from both new 
and existing shareholders. The execution of the capital increase is 
based on the resolution passed at the Company´s annual general 
meeting on May 25, 2010 to issue 20,588,705 new shares, which will 
result in a total of 41,413,846 shares issued and outstanding. 
Subscription rights have been granted to the shareholders. The 
subscription price was EUR 3.81 per share.
"We are very pleased to be able to successfully complete this 
financing," said Torsten Hombeck, Ph.D., Chief Financial Officer of 
Agennix.  "The funds raised are expected to enable us to obtain 
topline data in the ongoing Phase III FORTIS-M trial with oral 
talactoferrin in non-small cell lung cancer.  As of September 30 
2010, 443 patients or approximately 62% of a total 720 patients were 
enrolled in FORTIS-M, and we continue to expect topline data from 
this trial by the end of 2011."
Dr. Hombeck continued: "With funds raised in the offering, we also 
plan to initiate a Phase III trial with talactoferrin in severe 
sepsis, an area of major unmet medical need.  This trial is expected 
to start in early 2011.  The money raised will also enable us to 
continue other important activities, including additional R&D work 
such as initiating a Phase I trial in hematological tumors with our 
multi-targeted kinase inhibitor, RGB-286638, as well as expanding 
production capacity for oral talactoferrin."
In the capital increase, approximately 29% of the 20,588,705 new 
shares were subscribed in the rights offering and approximately 71% 
of the shares were purchased by new institutional investors in a 
private placement or by dievini Hopp BioTech holding GmbH & Co. KG 
under a firm commitment agreement.
Following the completion of this offering, dievini will hold 
approximately 59% of shares outstanding in Agennix.  Dievini has 
informed the Company that it has not yet received a decision from the
German Federal Financial Supervisory Authority (Bundesanstalt fuer 
Finanzdienstleistungsaufsicht) (BaFin) regarding dievini´s 
application for an exemption from the obligation to make a mandatory 
tender offer.  Dievini applied for this exemption in case it acquired
control of the Company in the meaning of Section 29 (2) of the German
Takeover Act through participation in the capital increase.
The entry of the capital increase in the commercial register of the 
local court in Mannheim is expected to occur on or around October 4, 
2010. The new shares will be listed on the Frankfurt Stock Exchange 
and are expected to begin trading on or around October 5, 2010.  The 
Joint Global Coordinators for the transaction were Piper Jaffray Ltd.
and WestLB AG.
About Agennix
Agennix AG is a publicly listed biopharmaceutical company that is 
focused on the development of novel therapies that have the potential
to substantially improve the length and quality of life of critically
ill patients in areas of major unmet medical need. The Company´s most
advanced program is talactoferrin, an oral therapy that has 
demonstrated activity in randomized, double-blind, placebo-controlled
Phase II studies in non-small cell lung cancer, as well as in severe 
sepsis. Talactoferrin is currently in Phase III clinical trials in 
non-small cell lung cancer, and Agennix plans to develop this program
further for the treatment of severe sepsis. Other clinical 
development programs include RGB-286638, a multi-targeted kinase 
inhibitor in Phase I testing; the oral platinum-based compound 
satraplatin; and a topical gel form of talactoferrin for diabetic 
foot ulcers. Agennix´s registered seat is in Heidelberg, Germany. The
Company has three sites of operation: Planegg/Munich, Germany; 
Princeton, New Jersey and Houston, Texas. For additional information,
please visit the Agennix Web site at www.agennix.com.
This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of Agennix AG.
Such statements are based on current expectations and are subject to 
risks and uncertainties, many of which are beyond our control, that 
could cause future results, performance or achievements to differ 
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Actual results could 
differ materially depending on a number of factors, and we caution 
investors not to place undue reliance on the forward-looking 
statements contained in this press release. Forward-looking 
statements speak only as of the date on which they are made and 
Agennix undertakes no obligation to update these forward-looking 
statements, even if new information becomes available in the future.
This press release is not for distribution, directly or indirectly, 
in or into the United States (including its territories and 
possessions, any State of the United States and the District of 
Columbia). These materials do not constitute or form a part of any 
offer or solicitation to purchase or subscribe for securities in the 
United States of America. The shares in Agennix AG (the "Shares") 
mentioned herein may not be offered or sold in the United States 
absent registration or an exemption from registration under the U.S. 
Securities Act of 1933, as amended (the "Securities Act").
The Shares have not been, and will not be, registered under the 
Securities Act and will not be offered or sold in the United States, 
except on the basis of applicable exemptions from registration. There
will be no public offering of securities in the United States.
For further information, please contact:
Agennix AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693 
ir@agennix.com
In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com
Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Phone: +49 (0) 89 210 228 0 
raimund.gabriel@mc-services.eu
Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325 
lwilliams@troutgroup.com
end of announcement                               euro adhoc

Further inquiry note:

Investor Relations & Corporate Communications
Tel.: +49 (0) 89 8565 2693
E-Mail: ir@agennix.com

Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade

Plus de actualités: AGENNIX AG
Plus de actualités: AGENNIX AG